Literature DB >> 11724856

Laboratory diagnosis of common herpesvirus infections of the central nervous system by a multiplex PCR assay.

P Markoulatos1, A Georgopoulou, N Siafakas, E Plakokefalos, G Tzanakaki, J Kourea-Kremastinou.   

Abstract

A sensitive multiplex PCR assay for single-tube amplification that detects simultaneous herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella-zoster virus (VZV), human cytomegalovirus (CMV), and Epstein-Barr virus (EBV) is reported with particular emphasis on how the method was optimized and carried out and its sensitivity was compared to previously described assays. The assay has been used on a limited number of clinical samples and must be thoroughly evaluated in the clinical context. A total of 86 cerebrospinal fluid (CSF) specimens from patients which had the clinical symptoms of encephalitis, meningitis or meningoencephalitis were included in this study. The sensitivity of the multiplex PCR was determined to be 0.01 and 0.03 50% tissue culture infective doses/the reciprocal of the highest dilution positive by PCR for HSV-1 and HSV-2 respectively, whereas for VZV, CMV and EBV, 14, 18, and 160 ag of genomic DNA were detected corresponding to 48, 66, and 840 genome copies respectively. Overall, 9 (10.3%) of the CSF samples tested were positive in the multiplex PCR. HSV-1 was detected in three patients (3.5%) with encephalitis, VZV was detected in four patients (4.6%) with meningitis, HSV-2 was detected in one neonate (1.16%), and CMV was also detected in one neonate (1.16%). None of the samples tested was positive for the EBV genome. None of the nine positive CSF samples presented herpesvirus coinfection in the central nervous system. Failure of DNA extraction or failure to remove any inhibitors of DNA amplification from CSF samples was avoided by the inclusion in the present multiplex PCR assay of alpha-tubulin primers. The present multiplex PCR assay detects simultaneously five different herpesviruses and sample suitability for PCR in a single amplification round of 40 cycles with an excellent sensitivity and can, therefore, provide an early, rapid, reliable noninvasive diagnostic tool allowing the application of antiviral therapy on the basis of a specific viral diagnosis. The results of this preliminary study should prompt a more exhaustive analysis of the clinical value of the present multiplex PCR assay.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724856      PMCID: PMC88560          DOI: 10.1128/JCM.39.12.4426-4432.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Amplification and characterization of herpesvirus DNA in cerebrospinal fluid from patients with acute encephalitis.

Authors:  F Rozenberg; P Lebon
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

2.  Intrathecal production of specific IgA antibodies in CNS infections.

Authors:  M Roberg; P Forsberg; A Tegnell; K Ekerfeldt
Journal:  J Neurol       Date:  1995-06       Impact factor: 4.849

3.  New method for the extraction of viral RNA and DNA from cerebrospinal fluid for use in the polymerase chain reaction assay.

Authors:  I Casas; L Powell; P E Klapper; G M Cleator
Journal:  J Virol Methods       Date:  1995-05       Impact factor: 2.014

Review 4.  Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations.

Authors:  R J Whitley; F Lakeman
Journal:  Clin Infect Dis       Date:  1995-02       Impact factor: 9.079

5.  Detection of varicella-zoster virus-specific DNA sequences in cerebrospinal fluid from patients with acute aseptic meningitis and no cutaneous lesions.

Authors:  J M Echevarría; I Casas; A Tenorio; F de Ory; P Martínez-Martín
Journal:  J Med Virol       Date:  1994-08       Impact factor: 2.327

6.  Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

Authors:  F D Lakeman; R J Whitley
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

7.  Herpes simplex encephalitis. Early diagnosis and immune activation in the acute stage and during long-term follow-up.

Authors:  E Aurelius
Journal:  Scand J Infect Dis Suppl       Date:  1993

8.  Cytomegalovirus infection of the CNS in non-compromised patients.

Authors:  M Studahl; A Ricksten; T Sandberg; S Elowson; S Herner; C Säll; T Bergström
Journal:  Acta Neurol Scand       Date:  1994-06       Impact factor: 3.209

9.  Evaluation of the polymerase chain reaction for diagnosis of herpes simplex virus encephalitis.

Authors:  E Puchhammer-Stöckl; F X Heinz; M Kundi; T Popow-Kraupp; G Grimm; M M Millner; C Kunz
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

10.  Significance and clinical relevance of the detection of herpes simplex virus DNA by the polymerase chain reaction in cerebrospinal fluid from patients with presumed encephalitis.

Authors:  T Guffond; A Dewilde; P E Lobert; D Caparros-Lefebvre; D Hober; P Wattre
Journal:  Clin Infect Dis       Date:  1994-05       Impact factor: 9.079

View more
  34 in total

1.  Multiplex PCR: rapid DNA cycling in a conventional thermal cycler.

Authors:  P Markoulatos; N Siafakas; T Katsorchis; M Moncany
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

2.  Membrane adsorption with direct cell culture combined with reverse transcription-PCR as a fast method for identifying enteroviruses from sewage.

Authors:  D Papaventsis; N Siafakas; P Markoulatos; G T Papageorgiou; C Kourtis; E Chatzichristou; C Economou; S Levidiotou
Journal:  Appl Environ Microbiol       Date:  2005-01       Impact factor: 4.792

3.  Evaluation of MeningoFinder, a novel multiplex ligation-dependent probe amplification assay for simultaneous detection of six virus species causing central nervous system infections.

Authors:  P F G Wolffs; C Vink; J Keijdener; B Habek; M Reijans; G Simons; C A Bruggeman; A J C van den Brule
Journal:  J Clin Microbiol       Date:  2009-06-24       Impact factor: 5.948

4.  Development and padronization of three multiplex PCRs for the diagnosis of Chlamydia trachomatis, Toxoplasma gondii, herpes simplex viruses 1 and 2, and Cytomegalovirus.

Authors:  Danielle A G Zauli; Carla Lisandre Paula de Menezes; Cristiane Lommez de Oliveira
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

5.  Rapid virological diagnosis of central nervous system infections by use of a multiplex reverse transcription-PCR DNA microarray.

Authors:  Nicolas Leveque; Adrien Van Haecke; Fanny Renois; David Boutolleau; Deborah Talmud; Laurent Andreoletti
Journal:  J Clin Microbiol       Date:  2011-09-14       Impact factor: 5.948

6.  DNA microarrays for virus detection in cases of central nervous system infection.

Authors:  Yury S Boriskin; Philip S Rice; Richard A Stabler; Jason Hinds; Hasan Al-Ghusein; Keith Vass; Philip D Butcher
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

Review 7.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Detection of multiple human herpes viruses by DNA microarray technology.

Authors:  Zeno Földes-Papp; Renate Egerer; Eckhard Birch-Hirschfeld; Hans-Martin Striebel; Ulrike Demel; Gernot P Tilz; Peter Wutzler
Journal:  Mol Diagn       Date:  2004

9.  Detection of Cytomegalovirus in Bronchoalveolar Lavage Fluid from HIV-Positive Individuals with Community Acquired Pneumonia.

Authors:  Arati Mane; Pankaj Gujar; Shraddha Gaikwad; Tilak Dhamgaye; Arun Risbud
Journal:  J Clin Diagn Res       Date:  2017-07-01

10.  Clinical validation of a new triplex real-time polymerase chain reaction assay for the detection and discrimination of Herpes simplex virus types 1 and 2.

Authors:  Heide Reil; Ariane Bartlime; Jana Drerup; Thomas Grewing; Klaus Korn
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.